Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309830 | 0.91 | IGF1R (0.32) | JAK2JAK1IGF1R | |
| SCHEMBL24310693 | 0.90 | EGFR (0.33) | BTKAURKAAURKB | |
| SCHEMBL24309551 | 0.89 | FYN (0.32) | TNK2FYN | |
| SCHEMBL24309823 | 0.88 | AURKA (0.38) | JAK2BTKAURKAAURKB | |
| SCHEMBL24309744 | 0.87 | LTA4H (0.38) | TNK2IGF1RBTK | |
| SCHEMBL24309922 | 0.85 | F10 (0.40) | — | |
| SCHEMBL24310179 | 0.83 | IGF1R (0.31) | JAK2JAK1IGF1R | |
| SCHEMBL24309723 | 0.82 | JAK2 (0.34) | JAK2JAK1IGF1RNR1H4 | |
| SCHEMBL24309901 | 0.81 | IGF1R (0.33) | JAK2JAK1IGF1R | |
| SCHEMBL24309917 | 0.81 | MAPK14 (0.33) | JAK2JAK1IGF1RBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |